Description: Quest PharmaTech Inc. is a Canada-based pharmaceutical company. The Company, through its subsidiary, OncoQuest Inc., is developing immunotherapies for cancer treatment. It operates through two segments: biopharmaceutical/pharmaceutical products and consumer/cosmetic products. OncoQuest's technology platform includes a panel of tumor antigen specific monoclonal immunoglobulins, including CA125, MUC1, PSA, and Her2/neu, and the application of combinatorial immunotherapy. OncoQuest's lead product, oregovomab, is undergoing a Phase IIb clinical trial involving approximately 80 ovarian cancer patients in Italy and the United States. OncoQuest's pipeline of product candidates consists of four other monoclonal antibodies targeting certain tumor antigens that are presented in a range of cancers, including such cancers as breast, lung, pancreas, stomach and prostate. It also markets consumer health products around the world, including Bellus Skin serum, an anti-wrinkle skin care product.
Home Page: www.questpharmatech.com
QPT Technical Analysis
8123 Roper Road NW
Edmonton,
AB
T6E 6S4
Canada
Phone:
780 448 1400
Officers
| Name | Title |
|---|---|
| Dr. Ragupathy Madiyalakan Ph.D. | CEO & Director |
| Mr. Pierre Vermette | Chief Financial Officer |
| Mr. Roger Andrews | Head of Investor Relations & Corp. Communications |
| Mr. Douglas C. Bachman | VP of Corp. Devel. |
| Mr. Thomas Woo | VP of Product Devel. |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1139 |
| Price-to-Sales TTM: | 515.9739 |
| IPO Date: | |
| Fiscal Year End: | January |
| Full Time Employees: | 0 |